These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases]. Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
5. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901 [TBL] [Abstract][Full Text] [Related]
6. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid. Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439 [TBL] [Abstract][Full Text] [Related]
7. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. Trump DL; Elson PJ; Borden EC; Harris JE; Tuttle RL; Whisnant JK; Oken MM; Carignan JR; Ruckdeschel JC; Davis TE Cancer Treat Rep; 1987 Feb; 71(2):165-9. PubMed ID: 3802113 [TBL] [Abstract][Full Text] [Related]
8. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Bukowski RM Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599 [TBL] [Abstract][Full Text] [Related]
9. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820 [TBL] [Abstract][Full Text] [Related]
10. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial. Figlin RA; deKernion JB; Maldazys J; Sarna G Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656 [TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Rinehart J; Malspeis L; Young D; Neidhart J Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886 [TBL] [Abstract][Full Text] [Related]
13. [Sequential combination therapy with alpha interferon and OK-432 (streptococcal preparation) against advanced renal cell carcinoma]. Marumo K; Mura M; Deguchi N; Baba S; Jitsukawa S; Nakazono M; Tazaki H Gan To Kagaku Ryoho; 1986 Jul; 13(7):2434-9. PubMed ID: 3729498 [TBL] [Abstract][Full Text] [Related]
14. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J; J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421 [TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. Quesada JR; Evans L; Saks SR; Gutterman JU J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511 [TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
18. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy. Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era. Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma. Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]